News Release

Herbert A. Fleisch ESCEO-IOF Medal awarded to Dr. Helena Johansson

Swedish investigator is honored for her exceptional achievements at the opening of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Florence, Italy

Grant and Award Announcement

International Osteoporosis Foundation

Dr Helena Johansson, a leading statistician in the field of osteoporosis, has been awarded the prestigious Herbert A. Fleisch ESCEO-IOF Medal during the opening ceremony of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

The Herbert A. Fleisch ESCEO-IOF Medal recognizes a researcher who has made outstanding achievements in bone and osteoporosis research. The Award is named after the late Professor Herbert A. Fleisch, a renowned investigator whose groundbreaking work contributed to the development of the field of scientific knowledge about metabolic bone diseases and their treatment.

Professor Jean-Yves Reginster, ESCEO President and Co-Chair of WCO-IOF-ESCEO 2017 stated: "Named in honour of a pioneer in osteoporosis research, this prestigious Award appropriately recognizes an individual who has considerably influenced progress in the bone field. Indeed, Dr Johansson's innovative work in the development of the fracture risk assessment (FRAX) tool has made a lasting and significant contribution to the broader osteoporosis field. Thanks to her contribution, FRAX has become an essential tool in support of informed clinical assessment and patient management in 63 countries around the world."

Dr Helena Johansson is an internationally recognized statistician in the field of osteoporosis and is the principal architect of the country-specific FRAX models, which involves the application of FRAX equations to the epidemiology of mortality and fracture in each country. She has been instrumental in the meta-analyses that underpins the FRAX tool, and has also contributed to the development of clinical practice guidelines in relation to FRAX. She is the author of more than 140 peer reviewed papers on bone disease and metabolism. Dr Johansson is currently a consulting statistician at the University of Gothenburg; a member of the FRAX group, Centre for Metabolic Bone Diseases, University of Sheffield; adjunct associate professor at the Institute for Health and Aging, Catholic University of Australia in Melbourne; member of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Scientific Advisory Board; and member of the International Osteoporosis Foundation (IOF) Committee of Scientific Advisors. She is the recipient of several awards, including the ASBMR Gap Award, the ESCEO-AMGEN Fellowship Award, and the American Society of Bone and Mineral Research Young Investigator Award.


World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO Florence 2017):

Held jointly by IOF and ESCEO, the Congress takes place in Florence, Italy, from March 23-26, 2017. WCO-IOF-ESCEO is the world's largest annual forum for the presentation of clinical research and new advances in the prevention and management of bone, muscle and joint disorders, including sarcopenia and frailty. Congress abstracts will be published in Osteoporosis International, Volume 28, Supplement 1, March 2017. For complete information visit #OsteoCongress

About IOF:

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 237 patient, medical and research societies in 99 locations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. @iofbonehealth

About ESCEO:

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis & Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.